Severe adenovirus pneumonia requiring extracorporeal membrane oxygenation support – Serotype 7 revisited

Low, Su Ying; Tan, Thuan Tong; Lee, C.H.K.; Loo, Chian Min; Chew, Huck Chin

doi:10.1016/j.rmed.2013.09.008

Cited by 21 publications

(21 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Therefore, the early initiation of ECMO seems to be an intriguing option to protect the lungs of these critically ill patients (MacLaren et al 2012; Turner and Cheifetz 2013). In a case series in Low et al (2013), the duration of pre-ECMO mechanical ventilation was 2, 5, and 16 days, while in Sun et al (2014), it was 2–13 days, which were longer than in our two cases (i.e., 47 and 15 h, respectively). We also applied lung rest ventilation to the patients, as recommended by the Extracorporeal Life Support Organization (ELSO).…”

Section: Discussioncontrasting

confidence: 58%

“…Sun et al (2014) described five patients with severe ARDS with confirmed HAdV-55 infection, four of whom received VV ECMO. Low et al (2013) reported three patients with confirmed HAdV-7 ARDS who were treated with VV ECMO; the reported survival rates were poor. Prodhan et al (2014) also reported that only 62 (38.0%) of 163 children with adenovirus pneumonia supported using ECMO survived.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Severe ARDS caused by adenovirus: early initiation of ECMO plus continuous renal replacement therapy

Kim

Park

et al. 2016

SpringerPlus

View full text Add to dashboard Cite

The reported survival rates of patients with acute respiratory distress syndrome (ARDS) caused by human adenovirus (HAdV) pneumonia are poor. The results do not differ much in immunocompetent patients supported by extracorporeal membrane oxygenation (ECMO). We report two immunocompetent patients with severe ARDS complicating HAdV pneumonia who were treated successfully and survived to discharge. Compared with previous cases, our cases might have benefited from several factors. First, the time interval between mechanical ventilator support and ECMO implantation was shorter. Second, we implemented conservative fluid management as recommended by the ARDS network using continuous renal replacement therapy (CRRT). Third, we administered an antiviral agent as early as possible. A clinical trial of early ECMO with CRRT and the administration of cidofovir in patients with severe ARDS complicating HAdV pneumonia are needed to confirm our results.

show abstract

Section: Discussioncontrasting

confidence: 58%

Section: Discussionmentioning

confidence: 99%

Severe ARDS caused by adenovirus: early initiation of ECMO plus continuous renal replacement therapy

Kim

Park

et al. 2016

SpringerPlus

View full text Add to dashboard Cite

show abstract

“…Recently, more and more ARD outbreaks with severe or even fatal cases caused by HAdV-7 have been reported in Asia, especially in China, which has a large and high-density population161113151628293031. The three recent isolates circulating in Southern China (DG01; 2011), Southwestern China (CQ1198; 2010), and Northwestern China (0901HZ/ShX; 2009) were identified as a re-emergent genome type 7d (HAdV-7d) after approximately 20-year absence in China1.…”

mentioning

confidence: 99%

Fatal Community-acquired Pneumonia in Children Caused by Re-emergent Human Adenovirus 7d Associated with Higher Severity of Illness and Fatality Rate

Zeng

Zhang

et al. 2016

Sci Rep

View full text Add to dashboard Cite

Human adenoviruses (HAdVs) are highly contagious pathogens causing acute respiratory disease (ARD), such as community-acquired pneumonia. HAdV-7d, a re-emergent genomic variant, has been recently reported in Asia and the United States after a several-decade absence. However, whether HAdV-7d is associated with higher severity than other types is currently unclear. In this study, the clinical and epidemiological investigation showed that fever, cough, and sore throat were the three most common respiratory symptoms of HAdV infections. HAdV-7 caused longer duration of fever, higher morbidity of tachypnea/dyspnea, pleural effusion, diarrhea, hepatosplenomegaly, consciousness alteration, as well as higher rates of pneumonia, mechanical ventilation and higher fatality rate (28.6%) than other types, particularly HAdV-3 and HAdV-2. The genomes of seven HAdV-7d isolates from mild, severe, and fatal cases were sequenced and highly similar with each other. Surprisingly, two isolates (2011, 2012) had 100% identical genomes with an earlier strain from a fatal ARD outbreak in China (2009), which elucidates the virus origin and confirms the unexpected HAdV genomic conservation and stability. Phylogenetic analysis indicated that L1 52/55-kDa DNA packaging protein may be associated with the higher severity of illness and fatality rate of HAdV-7. Clinicians need to be aware of HAdVs in children with ARD.

show abstract

“…In particular, respiratory infections with human adenovirus 7 (HAdV7) have a well-documented association with severe clinical manifestations, nosocomial transmission, prolonged hospitalizations, pulmonary sequela, and deaths ( 1 − 6 ). Adenovirus pneumonia among immunocompetent adults is still relatively infrequent and therefore attracts considerable attention ( 4 ). …”

mentioning

confidence: 99%

Severe Infections with Human Adenovirus 7d in 2 Adults in Family, Illinois, USA, 2014

Kajon

Ison

2016

Emerg. Infect. Dis.

View full text Add to dashboard Cite

show abstract

Severe adenovirus pneumonia requiring extracorporeal membrane oxygenation support – Serotype 7 revisited

Cited by 21 publications

References 21 publications

Severe ARDS caused by adenovirus: early initiation of ECMO plus continuous renal replacement therapy

Severe ARDS caused by adenovirus: early initiation of ECMO plus continuous renal replacement therapy

Fatal Community-acquired Pneumonia in Children Caused by Re-emergent Human Adenovirus 7d Associated with Higher Severity of Illness and Fatality Rate

Severe Infections with Human Adenovirus 7d in 2 Adults in Family, Illinois, USA, 2014

Contact Info

Product

Resources

About